Smith+Nephew has lowered its revenue growth forecast for 2026, citing persistent weakness in its US orthopaedics division.
The UK-based medical products manufacturer reported that tighter cost controls helped push half-year profit ahead of expectations, but the top-line outlook remains under pressure from the underperforming American unit.
The divergence between operational efficiency and revenue generation highlights the structural challenges facing the company.
While management has successfully contained expenses to support bottom-line results, the inability to drive growth in the critical US market has forced a more cautious stance on full-year revenue projections.
This development adds to a broader trend of caution among healthcare and industrial firms navigating a softening demand environment.
The company’s decision to trim its outlook signals that near-term headwinds in the US orthopaedics sector are likely to persist, potentially impacting investor sentiment and valuation multiples in the medium term.